Evaluation of Hepatoprotective Potential of Polyherbal Preparations in CCl₄-Induced Hepatotoxicity in Mice

Table 3

Dosage of orally administered drug in various groups in phenobarbitone-induced sleeping time.

Groups	Treatment
Group 11	Normal control; received distilled water for 7 days (p.o.) + phenobarbitone single dose on day 9.
Group 12	Pathological control; distilled water for 7 days (p.o.) + CCl4 single dose on day 8 + phenobarbitone single dose on day 9.
Group 13	Received holyliv formulation at 2.6 ml/kg BW/d for 7 days (p.o.) + CCl4 single dose on day 8 + phenobarbitone single dose on day 9.
Group 14	Received holyliv formulation at 5.2 ml/kg BW/d for 7 days (p.o.) + CCl4 single dose on day 8 + phenobarbitone single dose on day 9.
Group 15	Received heptaliv formulation at 2.6 ml/kg BW/d for 7 days (p.o.) + CCl4 single dose on day 8 + phenobarbitone single dose on day 9.
Group 16	Received heptaliv formulation at 5.2 ml/kg BW/d for 7 days (p.o.) + CCl4 single dose on day 8 + phenobarbitone single dose on day 9.
Group 17	Received icturn formulation at 2.6 ml/kg BW/d for 7 days (p.o.) + CCl4 single dose on day 8 + phenobarbitone single dose on day 9.
Group 18	Received icturn formulation at 5.2 ml/kg BW/d for 7 days (p.o.) + CCl4 single dose on day 8 + phenobarbitone single dose on day 9.
Group 19	Received J-Deenar formulation at 2.6 ml/kg BW/d for 7 days (p.o.) + CCl4 single dose on day 8 + phenobarbitone single dose on day 9.
Group 20	Received J-Deenar formulation at 5.2 ml/kg BW/d for 7 days (p.o.) + CCl4 single dose on day 8 + phenobarbitone single dose on day 9.